Evidence map›Paper›PMID 26230845›Full record

ArticlePloS one2015

Microenvironmental Modulation of Decorin and Lumican in Temozolomide-Resistant Glioblastoma and Neuroblastoma Cancer Stem-Like Cells.

Cristiano Farace, Jaime Antonio Oliver, Consolacion Melguizo, Pablo Alvarez, Pasquale Bandiera, Ana Rosa Rama, Giulia Malaguarnera, Raul Ortiz, Roberto Madeddu, Jose Prados

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.

  1. Biomarkers of tumor invasiveness in proteomics (Review).International journal of oncology · 2020
    Pooled it
  2. Article
  3. Decorin: matrix-based pan-cancer tumor suppressor.Molecular and cellular biochemistry · 2025
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Cancer Stem Cells and Their Therapeutic Usage.Advances in experimental medicine and biology · 2023
    Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Cancer stem cells in neuroblastoma therapy resistance.Cancer drug resistance (Alhambra, Calif.) · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 2 countries.

Cristiano FaraceDepartment of Biomedical Sciences, University of Sassari, Sassari, Italy.
Jaime Antonio OliverInstitute of Biopathology and Regenerative Medicine (IBIMER), Granada, Spain.
Consolacion MelguizoInstitute of Biopathology and Regenerative Medicine (IBIMER), Granada, Spain; Department of Anatomy and Embryology, University of Granada, Granada, Spain; Biosanitary Institute of Granada (ibs.Granada), SAS-University of Granada, Granada, Spain.
Pablo AlvarezInstitute of Biopathology and Regenerative Medicine (IBIMER), Granada, Spain; Biosanitary Institute of Granada (ibs.Granada), SAS-University of Granada, Granada, Spain.
Pasquale BandieraDepartment of Biomedical Sciences, University of Sassari, Sassari, Italy.
Ana Rosa RamaInstitute of Biopathology and Regenerative Medicine (IBIMER), Granada, Spain; Biosanitary Institute of Granada (ibs.Granada), SAS-University of Granada, Granada, Spain; Department of Health Science, University of Jaén, Jaén, Spain.
Giulia MalaguarneraResearch Center "The Great Senescence", University of Catania, Catania, Italy.
Raul OrtizInstitute of Biopathology and Regenerative Medicine (IBIMER), Granada, Spain; Biosanitary Institute of Granada (ibs.Granada), SAS-University of Granada, Granada, Spain; Department of Health Science, University of Jaén, Jaén, Spain.
Roberto MadedduDepartment of Biomedical Sciences, University of Sassari, Sassari, Italy; National Institute of Biostructures and Biosystem (INBB), Rome, Italy.
Jose PradosInstitute of Biopathology and Regenerative Medicine (IBIMER), Granada, Spain; Department of Anatomy and Embryology, University of Granada, Granada, Spain; Biosanitary Institute of Granada (ibs.Granada), SAS-University of Granada, Granada, Spain.
Instituto de Investigación Biosanitaria de Granada · ESUniversity of Sassari · ITIstituto Nazionale Biostrutture e Biosistemi · ITUniversidad de Granada · ESUniversidad de Jaén · ESUniversity of Catania · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The presence of cancer stem cells (CSCs) or tumor-initiating cells can lead to cancer recurrence in a permissive cell-microenvironment interplay, promoting invasion in glioblastoma (GBM) and neuroblastoma (NB). Extracellular matrix (ECM) small leucine-rich proteoglycans (SLRPs) play multiple roles in tissue homeostasis by remodeling the extracellular matrix (ECM) components and modulating intracellular signaling pathways. Due to their pan-inhibitory properties against receptor tyrosine kinases (RTKs), SLRPs are reported to exert anticancer effects in vitro and in vivo. However, their roles seem to be tissue-specific and they are also involved in cancer cell migration and drug resistance, paving the way to complex different scenarios. The aim of this study was to determine whether the SLRPs decorin (DCN) and lumican (LUM) are recruited in cell plasticity and microenvironmental adaptation of differentiated cancer cells induced towards stem-like phenotype. Floating neurospheres were generated by applying CSC enrichment medium (neural stem cell serum-free medium, NSC SFM) to the established SF-268 and SK-N-SH cancer cell lines, cellular models of GBM and NB, respectively. In both models, the time-dependent synergistic activation of DCN and LUM was observed. The highest DCN and LUM mRNA/protein expression was detected after cell exposure to NSC SFM for 8/12 days, considering these cells as SLRP-expressing (SLRP+) CSC-like. Ultrastructural imaging showed the cellular heterogeneity of both the GBM and NB neurospheres and identified the inner living cells. Parental cell lines of both GBM and NB grew only in soft agar + NSC SFM, whereas the secondary neurospheres (originated from SLRP+ t8 CSC-like) showed lower proliferation rates than primary neurospheres. Interestingly, the SLRP+ CSC-like from the GBM and NB neurospheres were resistant to temozolomide (TMZ) at concentrations >750 μM. Our results suggest that GBM and NB CSC-like promote the activation of huge quantities of SLRP in response to CSC enrichment, simultaneously acquiring TMZ resistance, cellular heterogeneity, and a quiescent phenotype, suggesting a novel pivotal role for SLRP in drug resistance and cell plasticity of CSC-like, allowing cell survival and ECM/niche modulation potential.

Indexed as

Tumor MicroenvironmentBrain NeoplasmsChondroitin Sulfate ProteoglycansDacarbazineDecorinGlioblastomaHumansKeratan SulfateLumicanNeoplastic Stem CellsNeuroblastomaTemozolomideChondroitin Sulfate ProteoglycansDacarbazineDecorinKeratan SulfateLumicanLUM protein, humanTemozolomide

Identifiers

PMID26230845
PMCPMC4521885
OpenAlexW1787940529

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.